Biogen Inc. (BIIB)
| Market Cap | 33.63B +64.6% |
| Revenue (ttm) | 10.03B +0.3% |
| Net Income | 834.60M -45.5% |
| EPS | 5.64 -46.1% |
| Shares Out | 147.75M |
| PE Ratio | 40.37 |
| Forward PE | 17.17 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 957,974 |
| Open | 228.27 |
| Previous Close | 226.36 |
| Day's Range | 223.76 - 228.92 |
| 52-Week Range | 135.39 - 229.19 |
| Beta | 0.17 |
| Analysts | Buy |
| Price Target | 238.18 (+4.65%) |
| Earnings Date | Oct 28, 2026 |
About BIIB
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar refe... [Read more]
Financial Performance
In 2025, Biogen's revenue was $9.89 billion, an increase of 2.22% compared to the previous year's $9.68 billion. Earnings were $1.29 billion, a decrease of -20.79%.
Financial StatementsAnalyst Summary
According to 35 analysts, the average rating for BIIB stock is "Buy." The 12-month stock price target is $238.18, which is an increase of 4.65% from the latest price.
News
Biogen publishes results from adolescent subgroup of VALIANT study
Biogen (BIIB) announced the publication of results from a prespecified adolescent subgroup analysis of the Phase 3 VALIANT study evaluating Empaveli in the Clinical Journal of the American Society of…
Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN
CAMBRIDGE, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the publication of results from a prespecified adolescent subgroup analysis of the Phase 3 VALIANT study...
Eisai, Biogen announce Leqembi Pen has been approved in Japan
Eisai (ESAIY) and Biogen (BIIB) announced that Leqembi Pen, the subcutaneous formulation of the anti-amyloid beta protofibril antibody Leqembi has been approved in Japan as a new route of administrati...
LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer's Disease
The First and Only Anti-Amyloid Treatment in Japan that Enable At-Home Administration for Alzheimer's Disease, a Progressive Disease The First and Only Anti-Amyloid Treatment in Japan that Enable At-H...
Biogen Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The company has transformed its strategy, expanding beyond neuroscience into immunology, nephrology, and other specialties through targeted acquisitions and pipeline diversification. Key assets like LEQEMBI, litifilimab, and felzartamab are expected to drive growth, with multiple late-stage trials and commercial launches anticipated over the next several years.
Biogen price target raised to $175 from $165 at HSBC
HSBC raised the firm’s price target on Biogen (BIIB) to $175 from $165 and keeps a Reduce rating on the shares. The firm adjusted targets in the healthcare group to…
Biogen Transcript: Wells Fargo 21st Annual Healthcare Conference
Management highlighted strategic diversification beyond neurology, disciplined capital allocation, and operational efficiency. Key growth drivers include a robust late-stage pipeline, expansion into nephrology and immunology, and commercial execution of new assets like felzartamab and SYFOVRE.
Stoke Therapeutics, Biogen present long-term data on Zorevunersen
“Stoke Therapeutics (STOK) and Biogen Inc. (BIIB) announced presentations of data at the 16th European Epilepsy Congress taking place September 5-9 in Athens, Greece. These data support the potential ...
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with R...
Biogen price target raised to $245 from $225 at Piper Sandler
Piper Sandler raised the firm’s price target on Biogen (BIIB) to $245 from $225 and keeps an Overweight rating on the shares. The firm cites post-Q2 model updates for the…
Biogen, Eisai announce NMPA of China approves subcutaneous Leqembi
Eisai (ESAIY) and Biogen (BIIB) announced that the National Medical Products Administration of China has approved the subcutaneous formulation, the anti-amyloid beta protofibril antibody Leqembi, as a...
LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer's Disease Approved in China
The First and Only Anti-Amyloid Therapy in China that Enables At-Home Administration for Alzheimer's Disease, a Progressive Neurodegenerative Disease The First and Only Anti-Amyloid Therapy in China t...
Stoke Therapeutics, Biogen present clinical data of Dravet syndrome candidate
Stoke Therapeutics (STOK) and Biogen (BIIB) announced presentations of data at the 16th European Epilepsy Congress September 5-9 in Athens. These data support the potential of zorevunersen as a first-...
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
–4-year data from the Phase 1/2a open-label extension (OLE) studies support the potential disease-modifying effects of zorevunersen–
Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer's Disease
TOKYO and CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd.
Biogen, Eisai announce positive recommendation for Leqembi in Canada
Eisai (ESAIY) and Biogen Canada (BIIB) announced receipt of the Canada’s Drug Agency’ final positive recommendation supporting public reimbursement for Leqembi, for eligible Canadians living with mild...
Biogen price target raised to $260 from $240 at RBC Capital
TRBC Capital raised the firm’s price target on Biogen (BIIB) to $260 from $240 and keeps an Outperform rating on the shares. The firm says the litifilimab data in Q4…
Eisai, Biogen announces once weekly lecanemab-irmb availability in the U.S.
Eisai (ESAIY) and Biogen (BIIB) announced that once weekly lecanemab-irmb subcutaneous injection is now available in the U.S. for initiation therapy for early Alzheimer’s disease in adults with mild c...
Biogen, Eisai announce Leqembi Iqlik now available in U.S.
Eisai (ESAIY) and Biogen (BIIB), announced that once weekly lecanemab-irmb subcutaneous injection is now available in the U.S. for initiation therapy for early Alzheimer’s disease in adults with mild ...
LEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease
LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing for initiation and maintenance (approved in the U.S.) LEQEMBI IQLIK is the first-of-its-kind anti-amyloi...
LEQEMBI IQLIK®(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease
LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing for initiation and maintenance (approved in the U.S.) TOKYO and CAMBRIDGE, Mass., Aug. 24, 2026 /PRNewsw...
Biogen upgraded to Outperform from Peer Perform at Wolfe Research
Wolfe Research upgraded Biogen (BIIB) to Outperform from Peer Perform with a $300 price target
Wolfe upgrades Biogen to Outperform on late-stage pipeline
Wolfe Research upgraded Biogen (BIIB) to Outperform from Peer Perform with a $300 price target The readouts for both litifilimab and felzartamab are “relative de-risked” and underappreciated at curren...
Expert explains why healthcare is a top-performing sector
Apollon Wealth Management CIO Eric Sterner discusses how technology is driving gains in the healthcare sector on ‘The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbus...
Biogen completes acquisition of RayThera
Biogen (BIIB) announced the completion of the acquisition of RayThera Inc., a privately held biotechnology company focused on discovering and developing small-molecule therapies in immunology. “The ac...